Approach
We build and capture value from company formation to Global/Asia asset accelerator to public investing
Our investment model
Incubation/
Early Stage
Panacea currently has incubators and venture builder operations in the US (Boston) and Asia (Shanghai, Singapore) to source and advance assets.
We collaborate with research institutes, individual inventors and industry entrepreneurs around the globe.
Global/Asia
Asset Accelerator
•In partnership with MNC pharma, we fund strategic collaborations globally and in CN to advance innovation opportunities in a P&L sparing manner.
Asset/technology partners are afforded the opportunity to expand the value of their platforms and even reach into white space areas guided by MNC pharma.
Acceleration activities are stewarded by Panacea’s dedicated team of translational experts in the US and Asia.
Public investing
By leveraging our venture-like discipline and acumen, we identify public opportunities with significant growth potential.
Investment Scope
We have built significant domain knowledge, network and experience in several key areas; and we continue to follow the science and expand our team aligned to these trends.
Therapeutics
Small Molecules: We look for highly differentiated assets anchored by the amalgamation of scientific merit, degree of unmet need, and evolving competitive dynamics.
Biologics: We believe there is significant room for unlocking of value from innovation in the antibody space as we move beyond existing targets and formats to new biology and advanced constructs.
Alternative modalities: We believe that oligotherapeutics, radionuclides together with advanced delivery will increasingly play a role in future therapeutic paradigms.
Cell and Gene Therapy
We look for new approaches to increase speed and affordability and to treat diseases of unmet need.
CXO
We invest in R&D and manufacturing services with advanced high entry barrier processes and innovative business models and also use these companies to benefit our own portfolio.